Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial

Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial

<p>Choroideremia is a rare, X-linked retinal degeneration resulting in progressive vision loss. A randomized, masked, phase 3 clinical trial evaluated the safety and efficacy over 12 months of follow-up in adult males with choroideremia randomized to receive a high-dose (1.0&thi...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	MacLaren, RE, Fischer, MD, Gow, JA, Lam, BL, Sankila, E-MK, Girach, A, Panda, S, Yoon, D, Zhao, G, Pennesi, ME
Format:	Journal article
Język:	English
Wydane:	Springer Nature 2023

Podobne zapisy

Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
od: Han, RC, i wsp.
Wydane: (2021)

Recent advances and future prospects in choroideremia
od: Zinkernagel MS, i wsp.
Wydane: (2015-11-01)

Macular hole surgery in patients with end-stage choroideremia
od: Zinkernagel, MS, i wsp.
Wydane: (2013)

Functional defects in color vision in patients with choroideremia
od: Jolly, J, i wsp.
Wydane: (2015)

Choroideremia: molecular mechanisms and development of AAV gene therapy
od: Patrício, M, i wsp.
Wydane: (2018)

Low luminance visual acuity and low luminance deficit in choroideremia and RPGR-associated retinitis pigmentosa
od: Wood, LJ, i wsp.
Wydane: (2021)

Prenylation of rab6a as a potency assay for choroideremia gene therapy
od: Patricio, M, i wsp.
Wydane: (2017)

Novel non-contiguous exon duplication in choroideremia
od: Edwards, T, i wsp.
Wydane: (2017)

Structural and functional characteristics of color vision changes in choroideremia
od: Jolly, JK, i wsp.
Wydane: (2021)

Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model
od: Halioua-Haubold, C-L, i wsp.
Wydane: (2019)

Longitudinal study to assess the quantitative use of fundus autofluorescence for monitoring disease progression in choroideremia
od: Dubis, AM, i wsp.
Wydane: (2021)

The spectrum of CHM gene mutations in choroideremia and their relationship to clinical phenotype
od: Simunovic, M, i wsp.
Wydane: (2016)

Retinal degeneration in choroideremia follows an exponential decay function
od: Aylward, J, i wsp.
Wydane: (2018)

Characterizing the natural history of visual function in choroideremia using microperimetry and multimodal retinal imaging
od: Jolly, J, i wsp.
Wydane: (2017)

Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
od: Chandler, LC, i wsp.
Wydane: (2021)

Structural and Functional Characteristics of Color Vision Changes in Choroideremia
od: Jasleen K. Jolly, i wsp.
Wydane: (2021-10-01)

Technique of retinal gene therapy: delivery of viral vector into the subretinal space
od: Xue, K, i wsp.
Wydane: (2017)

The biological activity of AAV vectors for choroideremia gene therapy can be measured by in vitro prenylation of RAB6A
od: Patrício, M, i wsp.
Wydane: (2018)

Visual acuity after retinal gene therapy for Choroideremia
od: Edwards, T, i wsp.
Wydane: (2016)

Retinal gene therapy in patients with choroideremia: Initial fi ndings from a phase 1/2 clinical trial
od: MacLaren, R, i wsp.
Wydane: (2014)

Macular hole surgery in patients with end-stage choroideremia.
od: Zinkernagel, MS, i wsp.
Wydane: (2013)

Ocular gene therapy for choroideremia: clinical trials and future perspectives
od: Xue, K, i wsp.
Wydane: (2018)

The Biological Activity of AAV Vectors for Choroideremia Gene Therapy Can Be Measured by In Vitro Prenylation of RAB6A
od: Maria I. Patrício, i wsp.
Wydane: (2018-06-01)

A dual variable Markov model to assess the potential benefits of choroideremia gene therapy on quality adjusted life years (QALYs)
od: Halioua-Haubold, C, i wsp.
Wydane: (2018)

Colour discrimination ellipses in choroideremia
od: Seitz, IP, i wsp.
Wydane: (2018)

Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
od: Xue, K, i wsp.
Wydane: (2018)

Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector.
od: Barnard, A, i wsp.
Wydane: (2014)

AAV2/2-CBA-REP1 Vector with WPRE Provides Functional Expression of the Transgene in Choroideremia Mouse Knock-Out and Patient Cells
od: Tolmachova, T, i wsp.
Wydane: (2012)

A detailed in vivo analysis of the retinal nerve fibre layer in choroideremia
od: Fu, D, i wsp.
Wydane: (2018)

Genetic testing for choroideremia
od: Abeshi Andi, i wsp.
Wydane: (2017-10-01)

A qualitative and quantitative assessment of fundus autofluorescence patterns in patients with choroideremia
od: Jolly, J, i wsp.
Wydane: (2016)

Long-term restoration of visual function in end-stage retinal degeneration using subretinal human melanopsin gene therapy
od: De Silva, SR, i wsp.
Wydane: (2017)

Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo
od: Tolmachova, T, i wsp.
Wydane: (2013)

Gene therapy for choroideremia using an adeno-associated viral vector encoding Rab escort protein 1: the REGENERATE open-label trial
od: Jasmina Cehajic-Kapetanovic, i wsp.
Wydane: (2024-05-01)

Correlation of optical coherence tomography and autofluorescence in the outer retina and choroid of patients with choroideremia
od: Xue, K, i wsp.
Wydane: (2016)

Iatrogenic choroidal neovascularization associated with subretinal gene therapy surgery
od: Kenneth W. Price, i wsp.
Wydane: (2022-09-01)

Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
od: Laurel C. Chandler, i wsp.
Wydane: (2021-09-01)

Changes in retinal sensitivity associated with cotoretigene toliparvovec in X-linked retinitis pigmentosa with RPGR gene variations
od: von Krusenstiern, L, i wsp.
Wydane: (2023)

Low‐contrast visual acuity versus low‐luminance visual acuity in choroideremia
od: Wood, L, i wsp.
Wydane: (2020)

Gene therapy for age-related macular degeneration
od: MacLaren, RE
Wydane: (2015)